Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ompenaclid + FOLFOX + bevacizumab
- Development stage
- Preclinical
- Lead developer
- Inspirna
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Ompenaclid + FOLFOX + bevacizumab is a three-drug combination therapy investigated or used for the treatment of metastatic colorectal cancer. The regimen consists of: - **Ompenaclid** (novel agent; mechanism and full development status in oncology not fully established publicly as of September 2025), - **FOLFOX** (a standard chemotherapy regimen comprising oxaliplatin, folinic acid [leucovorin], and fluorouracil [5-FU], which inhibits DNA synthesis and cell division in cancer cells), - **Bevacizumab** (a humanized monoclonal antibody targeting vascular endothelial growth factor [VEGF], inhibiting tumor angiogenesis)[2][3][1][5]. This combination harnesses cytotoxic activity (via FOLFOX) and antiangiogenic mechanisms (via bevacizumab) to treat advanced colorectal cancer. Ompenaclid is presumed to be a small molecule or targeted agent, but specific mechanistic details require further publication.
- Other names
- ompenaclid
02
Targets
TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)DNACKB (Creatine kinase B-type)SLC6A8 (Sodium- and chloride-dependent creatine transporter 1)
Beyond the preview
Go deeper on ompenaclid + FOLFOX + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ompenaclid + FOLFOX + bevacizumab.